Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.SwanBio raises $56m to advance new gene therapies for neurological conditions
This round was led by founding investors Syncona and Mass General Brigham Ventures. With this new funding round, SwanBio has so far raised $133m. SwanBio chair and chief
This round was led by founding investors Syncona and Mass General Brigham Ventures. With this new funding round, SwanBio has so far raised $133m. SwanBio chair and chief
Grupo Somar is an integrated pharmaceutical company with focus on developing, manufacturing, and marketing branded generic, private label and OTC products aimed at the private market and providing
This multi-year deal builds on the ongoing collaboration with AstraZeneca announced in June last year, to include the development of small molecule inhibitors targeting a second cancer-related epigenetic
Statera Biopharma president and CEO Michael K Handley said: “The strategic partnership with Lay Sciences has the potential to produce near term revenue. “The agreement allows Statera the
Additionally, the FDA’s Division of Neurology I granted its request for a pre-IND meeting for discussing a development path for elamipretide along with products within the approved exon-skipping
The company focuses on transforming the treatment of T Cell-mediated pathologies. New investors, Eli Lilly and Company and Sound Bioventures, took part in the financing round along with
The financing round saw participation from other new investors Pavilion Capital, Section 32, Invus and LifeSci Venture Partners. All of the Series A investors of Moma including Third
Under the agreement terms, Arvinas will leverage the Gemini Virtual Patient models of GNS to gain better understanding of the biology of the underlying disease. Arvinas will understand
The company will use these funds to expedite IN10018’s clinical trials that are currently underway for several types of cancer in the US as well as China, including
These patients have inadequate response to corticosteroids or other systemic therapies. Jakavi, an oral JAK 1 and JAK 2 tyrosine kinases inhibitor, was licensed by Novartis from Incyte